The DELIVER trial investigated clinical effects of dapagliflozin in over 6,000 patients with heart failure and mildly reduced or preserved ejection fraction. Prof. Scott Solomon draws a conclusion for cardiologists.
Image Source: DocCheck & Jesse Orrico, unsplash (mobile version)